# Study to Evaluate the Safety of Post-Operative TZP-101 (IV Ulimorelin) After Partial Bowel Resection

> **NCT01710982** · PHASE3 · COMPLETED · sponsor: **Norgine** · enrollment: 27 (actual)

## Conditions studied

- Postoperative Ileus

## Interventions

- **DRUG:** TZP-101
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01710982
- **Lead sponsor:** Norgine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01710982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01710982, "Study to Evaluate the Safety of Post-Operative TZP-101 (IV Ulimorelin) After Partial Bowel Resection". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01710982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*